Loading...
Loading...
Marty Makary’s abrupt resignation as FDA commissioner exposes deep tensions over e‑cigarette policy and political influence. Insiders say Makary resisted White House pressure to approve fruit‑flavored vapes—citing youth addiction risks—but the administration pushed authorizations and eased marketing rules, prompting his departure. The leadership change raises uncertainty at the agency amid vacancies for key center directors and a slow Senate confirmation outlook. Observers warn the move could shift regulatory priorities on tobacco, drug and vaccine reviews, and reflect broader clashes between public‑health concerns and industry or political interests shaping FDA decision‑making.
Leadership turmoil at the FDA affects regulatory stability for drugs, vaccines, and tobacco products, creating uncertainty for companies and clinicians relying on predictable review timelines. Tech professionals in health, biotech, and regulatory compliance need to reassess risk, timelines, and stakeholder engagement strategies.
Dossier last updated: 2026-05-20 09:40:43
The U.S. Food and Drug Administration is easing its stance on teen-risk products, giving the vaping industry two wins in May and withdrawing a proposed ban on minors using tanning beds. The FDA authorized its first fruit-flavored vaping products for adults—opposed by the American Academy of Pediatrics—and issued guidance saying it will not prioritize enforcement against some unauthorized vapes and nicotine pouches that have applied for authorization but are still under review, citing limited resources. Former Center for Tobacco Products director Mitch Zeller warned the policy could let illegal products sit beside authorized ones and confuse consumers. Reports say former commissioner Marty Makary reversed course under White House pressure. HHS spokesperson Rich Danker resigned in protest. In March, the FDA also pulled a decade-old tanning-bed proposal despite studies linking youth use to nearly triple melanoma risk.
Marty Makary resigned as FDA commissioner after reports that the White House had moved to oust him; President Trump confirmed the resignation and named Kyle Diamantas as acting commissioner. Sources say a key dispute was Trump’s push to authorize fruit‑flavored e‑cigarettes despite Makary’s concerns that such sign‑offs would reignite youth vaping and addiction. Insiders claim Makary resisted the approvals, clashing with the administration’s “save vaping” stance and tobacco industry interests. The departure follows public airing of tensions between Makary and the White House, and marks a rapid leadership change at the FDA with potential regulatory implications for tobacco, public health policy, and industry stakeholders.
Marty Makary resigned as FDA commissioner after a tumultuous 13-month tenure marked by internal criticism, unpredictable regulatory decisions, and political interference, leaving fresh uncertainty about the agency's direction. President Trump confirmed the departure and named Kyle Diamantas, head of the FDA's food center, to steer the agency during the transition. The Senate may lack bandwidth to confirm a permanent successor amid other high-profile nominations, and vacancies remain for key center directors overseeing drugs and biologics. Industry groups and lawmakers are divided: some praised Makary's independence while others cited management problems and shifting approval standards. The change raises questions about continuity on clinical trial streamlining and broader regulatory policy.
FDA Commissioner Marty Makary resigned Tuesday after clashing with the Trump White House, which had been preparing to fire him, according to Politico and The New York Times. President Donald Trump confirmed the resignation on social media and named FDA food regulator Kyle Diamantas as acting commissioner. People close to Makary said he quit after being pressured to authorize fruit-flavored e-cigarettes, which he had resisted over concerns about youth addiction. The Wall Street Journal reported Trump scolded Makary for delays in approving flavored vapes, including menthol, mango, and blueberry products from Los Angeles maker Glas; the FDA authorized them days later and issued a policy easing flavored-vape marketing. Makary also faced criticism over mifepristone review delays and vaccine-review changes aligned with HHS Secretary Robert F. Kennedy Jr.